4.6 Article

Human Medulloblastoma Cell Lines: Investigating on Cancer Stem Cell-Like Phenotype

Journal

CANCERS
Volume 12, Issue 1, Pages -

Publisher

MDPI
DOI: 10.3390/cancers12010226

Keywords

D283Med; cancer stem cell; stemness biomarkers; CD133; dielectrophoresis; cross-over frequency

Categories

Funding

  1. European Union's Horizon 2020 research and innovation program [737164 SUMCASTEC]
  2. ENEA 5 x Mille (Young investigator Project: New therapeutic strategies for the treatment of cancer)
  3. Fondazione AIRC per la Ricerca sul Cancro (AIRC, NANOCROSS project) [20314]
  4. Pediatric Research Institute Foundation [IRP18/06]
  5. Umberto Veronesi Foundation

Ask authors/readers for more resources

Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Despite the progress of new treatments, the risk of recurrence, morbidity, and death remains significant and the long-term adverse effects in survivors are substantial. The fraction of cancer stem-like cells (CSCs) because of their self-renewal ability and multi-lineage differentiation potential is critical for tumor initiation, growth, and resistance to therapies. For the development of new CSC-targeted therapies, further in-depth studies are needed using enriched and stable MB-CSCs populations. This work, aimed at identifying the amount of CSCs in three available human cell lines (DAOY, D341, and D283), describes different approaches based on the expression of stemness markers. First, we explored potential differences in gene and protein expression patterns of specific stem cell markers. Then, in order to identify and discriminate undifferentiated from differentiated cells, MB cells were characterized using a physical characterization method based on a high-frequency dielectrophoresis approach. Finally, we compared their tumorigenic potential in vivo, through engrafting in nude mice. Concordantly, our findings identified the D283 human cell line as an ideal model of CSCs, providing important evidence on the use of a commercial human MB cell line for the development of new strategic CSC-targeting therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available